Updated Guidance for Optimization of Medication Therapy for Heart Failure
This activity will educate clinicians on 2022 updates to the American College of Cardiology Foundation/American Heart Association/Heart Failure Society of America Guideline for the Management of Heart Failure. Research supports pharmacist's involvement with heart failure patients, who experience benefits such as decreases in heart failure hospitalizations, emergency department visits, and decreases in all-cause readmissions. This session will cover the latest clinical guideline updates for the treatment of heart failure so that pharmacists can use them in practice, contributing to positive patient outcomes. Using case-based questions, participants will be able to review what they have learned throughout the presentation.
At the completion of this activity, the participant should be able to:
- Describe the addition of SGLT2i’s in guideline directed medication therapy (GDMT) for HFrEF, HFmrEF and HFpEF based on the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure updates
- List the landmark trials supporting SGLT2i’s inclusion in heart failure treatment guidelines and their use in all classifications of heart failure
- Provide an optimization-based GDMT for patients with heart failure
Madeleine M. DePinho, B.S., PharmD., is a current PGY-1 acute care pharmacy resident at Mount Auburn Hospital in Cambridge, Massachusetts which is a part of the Beth Israel Lahey Health System. She has received both her Bachelor of Science and her Doctorate of Pharmacy from the University of Connecticut.
Course Fee: Free for MCPHS alumni, full-time staff, and for all other professionals.
Release Date: March 31, 2023
Expiration Date: March 31, 2024
ACPE UAN: 0026-0000-23-007-H01-P | Knowledge
Topic Designator: Drug Therapy
Contact Hours: 1 (0.1 CEU)
After registering or logging into mcphsce.org, you can view CE modules in our library.
Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Massachusetts College of Pharmacy and Health Sciences designates this activity for a total of 1.0 contact hour (0.1 CEU).
Massachusetts College of Pharmacy and Health Sciences adheres to the ACPE Standards for Integrity and Independence in Continuing Education. It is the policy of MCPHS that the speakers and planning committee members disclose all financial relationships with ineligible companies within the last 24 months, and that relevant conflicts of interest are mitigated. Speakers will disclose any off-label/unapproved use of drugs or devices during their presentation.
Madeleine DePinho, PharmD, holds no financial relationships with ineligible companies.
Content reviewers, Oussayma Moukhachen, PharmD, BCPS, BCCCP, and Brooke Harlow, PharmD, hold no financial relationships with ineligible companies.
Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies, related to the content of this presentation.
No funding from industry provided for this event. No exhibitors will be present.